rheumatic News
-
Remedica becomes a strategic partner of the Cyprus League against Rheumatism, in the framework of the Join Rheuma Kids Campaign
Remedica becomes a strategic partner of the Join Rheuma Kids campaign by the Cyprus League against Rheumatism and on the occasion of the World Day of Youth Rheumatic Diseases, on the 18th of March, Remedica supported the campaign for children with rheumatic diseases. The campaign aims to inform the general public regarding the prevention, diagnosis and treatment of childhood rheumatic diseases, ...
-
More Precise RA Patient Care; New data on the 14-3-3? blood test to help optimize treat-to-target strategies
At the annual European congress of rheumatology meeting, The European League Against Rheumatism (EULAR), taking place in Amsterdam on June 13th-16th, leading investigators from United States, Israel, and Egypt will present new data on the 14-3-3η blood test. Several of these studies grow the body of evidence of 14-3-3η’s key role as an early diagnostic test that assists with ...
-
Our AI application SURUS explained
Our Science team has been working hard on developing SURUS, our very own artificial intelligence application. Sounds fancy, but what does that actually mean, an artificial intelligence application? What is SURUS and why are we developing it? I’ll give you some more information on the ins and outs of SURUS. Background & Objective: why did we develop SURUS? Every day, healthcare ...
-
Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS-248 in patients with systemic sclerosis
Gesynta Pharma AB today announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis - a debilitating autoimmune disease that causes serious damage to the microvasculature. This proof-of-concept study will investigate the safety of GS-248 and its efficacy on Raynaud's phenomenon and peripheral blood flow in this ...
-
NIH study shows 32 million Americans have autoantibodies that target their own tissues
More than 32 million people in the United States have autoantibodies, which are proteins made by the immune system that target the body’s tissues and define a condition known as autoimmunity, a study shows. The first nationally representative sample looking at the prevalence of the most common type of autoantibody, known as antinuclear antibodies (ANA), found that the frequency of ANA is ...
-
Phase II update: Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248
Gesynta Pharma AB today announced that an IND (Investigational New Drug Application) has been submitted to the U.S. Food & Drug Administration for its oral drug candidate GS-248 in patients with systemic sclerosis. Concurrently, more than half of the patients in the ongoing Phase II study in four countries across Europe have been recruited. The study investigates the safety of GS-248 and ...
-
SetPoint Medical Receives FDA Breakthrough Device Designation for its Novel Bioelectronic Platform
SetPoint Medical, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel bioelectronic device for patients with rheumatoid arthritis (RA) who have incomplete response to, or are intolerant to multiple biologic drugs. The Company is developing its platform for the treatment of chronic, ...
-
SetPoint Medical Receives IDE Approval for U.S. Pivotal Trial to Study its Bioelectronic Platform in Rheumatoid Arthritis Patients
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to study its proprietary bioelectronic platform in patients with rheumatoid arthritis (RA). The multicenter, double-blind, randomized, sham ...
-
Why we need to drink hydrogen water and where can i buy hydrogen water
Olansi Healthcare Co., Ltd(Guangzhou Olans Water Treatment Equipments Co. Ltd) is a professional manufacturer in producing hydrogen water products,including hydrogen water maker,hydrogen water machine,hydrogen water filter,hydrogen water generators and hydrogen water bottle.hydrogen water makerIn our life,many people now more focus on their health.like water,many people choose hydrogen water.Does ...
-
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
Galapagos NV (Euronext & NASDAQ: GLPG) today announced its strategy for accelerated growth and value creation, its financial results for the first nine months of 2022, and the outlook for the remainder of 2022. The results are further detailed in the Q3 2022 financial report available on the financial reports section of the website. Forward, Faster strategy to accelerate innovation ...
By Galapagos NV
-
Why we need to drink hydrogen water and where can i buy hydrogen water
Olansi Healthcare Co., Ltd(Guangzhou Olans Water Treatment Equipments Co. Ltd) is a professional manufacturer in producing hydrogen water products,including hydrogen water maker,hydrogen water machine,hydrogen water filter,hydrogen water generators and hydrogen water bottle. hydrogen water maker In our life,many people now more focus on their health.like water,many people choose hydrogen ...
-
Dyve Biosciences Hosting Key Opinion Leader Webinar on Gout and DYV702
THOUSAND OAKS, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology company, today announced that it will host a key opinion leader (KOL) webinar on gout on Tuesday, November 23, 2021 at 11:00am Eastern Time. A live Q&A session will follow the formal presentations. To register for the event, please click HERE. The webinar will ...
-
First recipients of research grants to support genomic studies in Africa announced
African scientists will conduct genomic research on kidney disease, diabetes, heart disease, obesity, tuberculosis and African sleeping sickness through inaugural grants of the Human Heredity and Health in Africa Consortium (H3Africa). The grants were announced by the two funding organizations, the U.S. National Institutes of Health and the Wellcome Trust, a global charity based in London. The ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you